共 140 条
[1]
Laursen TM(2014)Excess early mortality in schizophrenia Annu Rev Clin Psychol. 10 425-48
[2]
Nordentoft M(2013)Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study Am J Psychiatry 170 324-33
[3]
Mortensen PB(2014)Prescription patterns for patients with schizophrenia in Korea: a focus on antipsychotic polypharmacy Clin Psychopharmacol Neurosci 12 128-36
[4]
Crump C(2009)Quality of life of patient with schizophrenia treated by conventional and atypical neuroleptics Tunis Med 87 593-8
[5]
Winkleby MA(2011)Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications Am Health Drug Benefits 4 292-302
[6]
Sundquist K(2015)Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings Schizophr Res 166 201-6
[7]
Sundquist J(2005)Ketter’s hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam Epilepsy Behav 6 366-72
[8]
Kim HY(2015)Glutamate and dopamine in schizophrenia: an update for the 21st century J Psychopharmacol 29 97-115
[9]
Lee HW(2011)Topiramate-induced weight loss: a review Epilepsy Res 95 189-99
[10]
Jung SH(2013)Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters Clin Schizophr Relat Psychoses 6 186-96